世界の呼吸器疾患治療薬市場予測 2020年-2025年

【英語タイトル】Global Respiratory Diseases Drugs Market Growth 2020-2025

LP Informationが出版した調査資料(LPI21MA10424)・商品コード:LPI21MA10424
・発行会社(調査会社):LP Information
・発行日:2021年1月(※2024年版があります。お問い合わせください)
・ページ数:167
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:化学・材料
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「呼吸器疾患治療薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、OTC、処方薬など、用途別には、病院、小売薬局などに区分してまとめた調査レポートです。呼吸器疾患治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・呼吸器疾患治療薬の世界市場概要(サマリー)
・呼吸器疾患治療薬の企業別販売量・売上
・呼吸器疾患治療薬の企業別市場シェア
・呼吸器疾患治療薬の世界市場規模 2015年-2020年:種類別(OTC、処方薬)
・呼吸器疾患治療薬の世界市場規模 2015年-2020年:用途別(病院、小売薬局)
・呼吸器疾患治療薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・呼吸器疾患治療薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・呼吸器疾患治療薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・呼吸器疾患治療薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・呼吸器疾患治療薬市場の成長要因・課題・動向
・呼吸器疾患治療薬の世界市場予測 2021年-2025年
・呼吸器疾患治療薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・呼吸器疾患治療薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・呼吸器疾患治療薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・呼吸器疾患治療薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・呼吸器疾患治療薬の世界市場予測:種類別(OTC、処方薬)
・呼吸器疾患治療薬の世界市場予測:用途別(病院、小売薬局)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Respiratory Diseases Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Respiratory Diseases Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Diseases Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Respiratory Diseases Drugs, covering the supply chain analysis, impact assessment to the Respiratory Diseases Drugs market size growth rate in several scenarios, and the measures to be undertaken by Respiratory Diseases Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
OTC
Rx Drugs

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Retail Pharmacy

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Biogen
Novartis
Pfizer
Novartis
Johnson & Johnson
Teva
Merck
EliLilly
AstraZeneca
Otsuka
Takeda

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Respiratory Diseases Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Respiratory Diseases Drugs market by identifying its various subsegments.
Focuses on the key global Respiratory Diseases Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Respiratory Diseases Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Respiratory Diseases Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Respiratory Diseases Drugs Consumption 2015-2025
2.1.2 Respiratory Diseases Drugs Consumption CAGR by Region
2.2 Respiratory Diseases Drugs Segment by Type
2.2.1 OTC
2.2.2 Rx Drugs
2.3 Respiratory Diseases Drugs Consumption by Type
2.3.1 Global Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Respiratory Diseases Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Respiratory Diseases Drugs Sale Price by Type (2015-2020)
2.4 Respiratory Diseases Drugs Segment by Application
2.4.1 Hospital
2.4.2 Retail Pharmacy
2.5 Respiratory Diseases Drugs Consumption by Application
2.5.1 Global Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Respiratory Diseases Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Respiratory Diseases Drugs Sale Price by Type (2015-2020)

3 Global Respiratory Diseases Drugs by Company
3.1 Global Respiratory Diseases Drugs Sales Market Share by Company
3.1.1 Global Respiratory Diseases Drugs Sales by Company (2018-2020)
3.1.2 Global Respiratory Diseases Drugs Sales Market Share by Company (2018-2020)
3.2 Global Respiratory Diseases Drugs Revenue Market Share by Company
3.2.1 Global Respiratory Diseases Drugs Revenue by Company (2018-2020)
3.2.2 Global Respiratory Diseases Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Respiratory Diseases Drugs Sale Price by Company
3.4 Global Respiratory Diseases Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Respiratory Diseases Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Respiratory Diseases Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Respiratory Diseases Drugs by Regions
4.1 Respiratory Diseases Drugs by Regions
4.2 Americas Respiratory Diseases Drugs Consumption Growth
4.3 APAC Respiratory Diseases Drugs Consumption Growth
4.4 Europe Respiratory Diseases Drugs Consumption Growth
4.5 Middle East & Africa Respiratory Diseases Drugs Consumption Growth

5 Americas
5.1 Americas Respiratory Diseases Drugs Consumption by Countries
5.1.1 Americas Respiratory Diseases Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Respiratory Diseases Drugs Value by Countries (2015-2020)
5.2 Americas Respiratory Diseases Drugs Consumption by Type
5.3 Americas Respiratory Diseases Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Respiratory Diseases Drugs Consumption by Regions
6.1.1 APAC Respiratory Diseases Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Respiratory Diseases Drugs Value by Regions (2015-2020)
6.2 APAC Respiratory Diseases Drugs Consumption by Type
6.3 APAC Respiratory Diseases Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Respiratory Diseases Drugs by Countries
7.1.1 Europe Respiratory Diseases Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Respiratory Diseases Drugs Value by Countries (2015-2020)
7.2 Europe Respiratory Diseases Drugs Consumption by Type
7.3 Europe Respiratory Diseases Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Respiratory Diseases Drugs by Countries
8.1.1 Middle East & Africa Respiratory Diseases Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Respiratory Diseases Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Respiratory Diseases Drugs Consumption by Type
8.3 Middle East & Africa Respiratory Diseases Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Respiratory Diseases Drugs Distributors
10.3 Respiratory Diseases Drugs Customer

11 Global Respiratory Diseases Drugs Market Forecast
11.1 Global Respiratory Diseases Drugs Consumption Forecast (2021-2025)
11.2 Global Respiratory Diseases Drugs Forecast by Regions
11.2.1 Global Respiratory Diseases Drugs Forecast by Regions (2021-2025)
11.2.2 Global Respiratory Diseases Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Respiratory Diseases Drugs Forecast by Type
11.8 Global Respiratory Diseases Drugs Forecast by Application

12 Key Players Analysis
12.1 Biogen
12.1.1 Company Information
12.1.2 Respiratory Diseases Drugs Product Offered
12.1.3 Biogen Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Biogen Latest Developments
12.2 Novartis
12.2.1 Company Information
12.2.2 Respiratory Diseases Drugs Product Offered
12.2.3 Novartis Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Novartis Latest Developments
12.3 Pfizer
12.3.1 Company Information
12.3.2 Respiratory Diseases Drugs Product Offered
12.3.3 Pfizer Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Pfizer Latest Developments
12.4 Novartis
12.4.1 Company Information
12.4.2 Respiratory Diseases Drugs Product Offered
12.4.3 Novartis Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Novartis Latest Developments
12.5 Johnson & Johnson
12.5.1 Company Information
12.5.2 Respiratory Diseases Drugs Product Offered
12.5.3 Johnson & Johnson Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Johnson & Johnson Latest Developments
12.6 Teva
12.6.1 Company Information
12.6.2 Respiratory Diseases Drugs Product Offered
12.6.3 Teva Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Teva Latest Developments
12.7 Merck
12.7.1 Company Information
12.7.2 Respiratory Diseases Drugs Product Offered
12.7.3 Merck Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Merck Latest Developments
12.8 EliLilly
12.8.1 Company Information
12.8.2 Respiratory Diseases Drugs Product Offered
12.8.3 EliLilly Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 EliLilly Latest Developments
12.9 AstraZeneca
12.9.1 Company Information
12.9.2 Respiratory Diseases Drugs Product Offered
12.9.3 AstraZeneca Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 AstraZeneca Latest Developments
12.10 Otsuka
12.10.1 Company Information
12.10.2 Respiratory Diseases Drugs Product Offered
12.10.3 Otsuka Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Otsuka Latest Developments
12.11 Takeda
12.11.1 Company Information
12.11.2 Respiratory Diseases Drugs Product Offered
12.11.3 Takeda Respiratory Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Takeda Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Respiratory Diseases Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of OTC
Table 5. Major Players of Rx Drugs
Table 6. Global Consumption Sales by Type (2015-2020)
Table 7. Global Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 8. Global Respiratory Diseases Drugs Revenue by Type (2015-2020) ($ million)
Table 9. Global Respiratory Diseases Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 10. Global Respiratory Diseases Drugs Sale Price by Type (2015-2020)
Table 11. Global Consumption Sales by Application (2015-2020)
Table 12. Global Respiratory Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 13. Global Respiratory Diseases Drugs Value by Application (2015-2020)
Table 14. Global Respiratory Diseases Drugs Value Market Share by Application (2015-2020)
Table 15. Global Respiratory Diseases Drugs Sale Price by Application (2015-2020)
Table 16. Global Respiratory Diseases Drugs Sales by Company (2017-2019) (K Units)
Table 17. Global Respiratory Diseases Drugs Sales Market Share by Company (2017-2019)
Table 18. Global Respiratory Diseases Drugs Revenue by Company (2017-2019) ($ Millions)
Table 19. Global Respiratory Diseases Drugs Revenue Market Share by Company (2017-2019)
Table 20. Global Respiratory Diseases Drugs Sale Price by Company (2017-2019)
Table 21. Global Respiratory Diseases Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 22. Players Respiratory Diseases Drugs Products Offered
Table 23. Respiratory Diseases Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 24. Global Respiratory Diseases Drugs Consumption by Regions 2015-2020 (K Units)
Table 25. Global Respiratory Diseases Drugs Consumption Market Share by Regions 2015-2020
Table 26. Global Respiratory Diseases Drugs Value by Regions 2015-2020 ($ Millions)
Table 27. Global Respiratory Diseases Drugs Value Market Share by Regions 2015-2020
Table 28. Americas Respiratory Diseases Drugs Consumption by Countries (2015-2020) (K Units)
Table 29. Americas Respiratory Diseases Drugs Consumption Market Share by Countries (2015-2020)
Table 30. Americas Respiratory Diseases Drugs Value by Countries (2015-2020) ($ Millions)
Table 31. Americas Respiratory Diseases Drugs Value Market Share by Countries (2015-2020)
Table 32. Americas Respiratory Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 33. Americas Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 34. Americas Respiratory Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 35. Americas Respiratory Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 36. APAC Respiratory Diseases Drugs Consumption by Regions (2015-2020) (K Units)
Table 37. APAC Respiratory Diseases Drugs Consumption Market Share by Regions (2015-2020)
Table 38. APAC Respiratory Diseases Drugs Value by Regions (2015-2020) ($ Millions)
Table 39. APAC Respiratory Diseases Drugs Value Market Share by Regions (2015-2020)
Table 40. APAC Respiratory Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 41. APAC Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 42. APAC Respiratory Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 43. APAC Respiratory Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 44. Europe Respiratory Diseases Drugs Consumption by Countries (2015-2020) (K Units)
Table 45. Europe Respiratory Diseases Drugs Consumption Market Share by Countries (2015-2020)
Table 46. Europe Respiratory Diseases Drugs Value by Countries (2015-2020) ($ Millions)
Table 47. Europe Respiratory Diseases Drugs Value Market Share by Countries (2015-2020)
Table 48. Europe Respiratory Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 49. Europe Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 50. Europe Respiratory Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 51. Europe Respiratory Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 52. Middle East & Africa Respiratory Diseases Drugs Consumption by Countries (2015-2020) (K Units)
Table 53. Middle East & Africa Respiratory Diseases Drugs Consumption Market Share by Countries (2015-2020)
Table 54. Middle East & Africa Respiratory Diseases Drugs Value by Countries (2015-2020) ($ Millions)
Table 55. Middle East & Africa Respiratory Diseases Drugs Value Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Respiratory Diseases Drugs Consumption by Type (2015-2020) (K Units)
Table 57. Middle East & Africa Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
Table 58. Middle East & Africa Respiratory Diseases Drugs Consumption by Application (2015-2020) (K Units)
Table 59. Middle East & Africa Respiratory Diseases Drugs Consumption Market Share by Application (2015-2020)
Table 60. Respiratory Diseases Drugs Distributors List
Table 61. Respiratory Diseases Drugs Customer List
Table 62. Global Respiratory Diseases Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 63. Global Respiratory Diseases Drugs Consumption Market Forecast by Regions
Table 64. Global Respiratory Diseases Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 65. Global Respiratory Diseases Drugs Value Market Share Forecast by Regions
Table 66. Global Respiratory Diseases Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 67. Global Respiratory Diseases Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 68. Global Respiratory Diseases Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 69. Global Respiratory Diseases Drugs Value Market Share Forecast by Type (2021-2025)
Table 70. Global Respiratory Diseases Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 71. Global Respiratory Diseases Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 72. Global Respiratory Diseases Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 73. Global Respiratory Diseases Drugs Value Market Share Forecast by Application (2021-2025)
Table 74. Biogen Product Offered
Table 75. Biogen Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 76. Biogen Main Business
Table 77. Biogen Latest Developments
Table 78. Biogen Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Novartis Product Offered
Table 80. Novartis Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 81. Novartis Main Business
Table 82. Novartis Latest Developments
Table 83. Novartis Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Pfizer Product Offered
Table 85. Pfizer Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 86. Pfizer Main Business
Table 87. Pfizer Latest Developments
Table 88. Pfizer Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Novartis Product Offered
Table 90. Novartis Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 91. Novartis Main Business
Table 92. Novartis Latest Developments
Table 93. Novartis Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Johnson & Johnson Product Offered
Table 95. Johnson & Johnson Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 96. Johnson & Johnson Main Business
Table 97. Johnson & Johnson Latest Developments
Table 98. Johnson & Johnson Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Teva Product Offered
Table 100. Teva Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 101. Teva Main Business
Table 102. Teva Latest Developments
Table 103. Teva Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Merck Product Offered
Table 105. Merck Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Merck Main Business
Table 107. Merck Latest Developments
Table 108. Merck Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 109. EliLilly Product Offered
Table 110. EliLilly Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 111. EliLilly Main Business
Table 112. EliLilly Latest Developments
Table 113. EliLilly Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. AstraZeneca Product Offered
Table 115. AstraZeneca Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 116. AstraZeneca Main Business
Table 117. AstraZeneca Latest Developments
Table 118. AstraZeneca Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Otsuka Product Offered
Table 120. Otsuka Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 121. Otsuka Main Business
Table 122. Otsuka Latest Developments
Table 123. Otsuka Basic Information, Company Total Revenue (in $ million), Respiratory Diseases Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Takeda Product Offered
Table 125. Takeda Respiratory Diseases Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2020E)
Table 126. Takeda Main Business
Table 127. Takeda Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 128. Takeda Latest Developments
List of Figures
Figure 1. Picture of Respiratory Diseases Drugs
Figure 2. Respiratory Diseases Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Respiratory Diseases Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Respiratory Diseases Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of OTC
Figure 7. Product Picture of Rx Drugs
Figure 8. Global Respiratory Diseases Drugs Consumption Market Share by Type (2015-2020)
Figure 9. Global Respiratory Diseases Drugs Value Market Share by Type (2015-2020)
Figure 10. Respiratory Diseases Drugs Consumed in Hospital
Figure 11. Global Respiratory Diseases Drugs Market: Hospital (2015-2020) (K Units)
Figure 12. Global Respiratory Diseases Drugs Market: Hospital (2015-2020) ($ Millions)
Figure 13. Respiratory Diseases Drugs Consumed in Retail Pharmacy
Figure 14. Global Respiratory Diseases Drugs Market: Retail Pharmacy (2015-2020) (K Units)
Figure 15. Global Respiratory Diseases Drugs Market: Retail Pharmacy (2015-2020) ($ Millions)
Figure 16. Global Respiratory Diseases Drugs Consumption Market Share by Application (2015-2020)
Figure 17. Global Respiratory Diseases Drugs Value Market Share by Application (2015-2020)
Figure 18. Global Respiratory Diseases Drugs Sales Market Share by Company in 2017
Figure 19. Global Respiratory Diseases Drugs Sales Market Share by Company in 2019
Figure 20. Global Respiratory Diseases Drugs Revenue Market Share by Company in 2017
Figure 21. Global Respiratory Diseases Drugs Revenue Market Share by Company in 2019
Figure 22. Global Respiratory Diseases Drugs Sale Price by Company in 2019
Figure 23. Global Respiratory Diseases Drugs Consumption Market Share by Regions 2015-2020
Figure 24. Global Respiratory Diseases Drugs Value Market Share by Regions 2015-2020
Figure 25. Americas Respiratory Diseases Drugs Consumption 2015-2020 (K Units)
Figure 26. Americas Respiratory Diseases Drugs Value 2015-2020 ($ Millions)
Figure 27. APAC Respiratory Diseases Drugs Consumption 2015-2020 (K Units)
Figure 28. APAC Respiratory Diseases Drugs Value 2015-2020 ($ Millions)
Figure 29. Europe Respiratory Diseases Drugs Consumption 2015-2020 (K Units)
Figure 30. Europe Respiratory Diseases Drugs Value 2015-2020 ($ Millions)
Figure 31. Middle East & Africa Respiratory Diseases Drugs Consumption 2015-2020 (K Units)
Figure 32. Middle East & Africa Respiratory Diseases Drugs Value 2015-2020 ($ Millions)
Figure 33. Americas Respiratory Diseases Drugs Consumption Market Share by Countries in 2019
Figure 34. Americas Respiratory Diseases Drugs Value Market Share by Countries in 2019
Figure 35. Americas Respiratory Diseases Drugs Consumption Market Share by Type in 2019
Figure 36. Americas Respiratory Diseases Drugs Consumption Market Share by Application in 2019
Figure 37. United States Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 38. United States Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 39. Canada Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 40. Canada Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 41. Mexico Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 42. Mexico Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 43. APAC Respiratory Diseases Drugs Consumption Market Share by Countries in 2019
Figure 44. APAC Respiratory Diseases Drugs Value Market Share by Regions in 2019
Figure 45. APAC Respiratory Diseases Drugs Consumption Market Share by Type in 2019
Figure 46. APAC Respiratory Diseases Drugs Consumption Market Share by Application in 2019
Figure 47. China Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 48. China Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 49. Japan Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 50. Japan Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 51. Korea Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 52. Korea Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 53. Southeast Asia Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 54. Southeast Asia Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 55. India Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 56. India Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 57. Australia Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 58. Australia Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 59. Europe Respiratory Diseases Drugs Consumption Market Share by Countries in 2019
Figure 60. Europe Respiratory Diseases Drugs Value Market Share by Countries in 2019
Figure 61. Europe Respiratory Diseases Drugs Consumption Market Share by Type in 2019
Figure 62. Europe Respiratory Diseases Drugs Consumption Market Share by Application in 2019
Figure 63. Germany Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 64. Germany Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 65. France Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 66. France Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 67. UK Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 68. UK Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 69. Italy Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 70. Italy Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 71. Russia Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 72. Russia Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 73. Middle East & Africa Respiratory Diseases Drugs Consumption Market Share by Countries in 2019
Figure 74. Middle East & Africa Respiratory Diseases Drugs Value Market Share by Countries in 2019
Figure 75. Middle East & Africa Respiratory Diseases Drugs Consumption Market Share by Type in 2019
Figure 76. Middle East & Africa Respiratory Diseases Drugs Consumption Market Share by Application in 2019
Figure 77. Egypt Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 78. Egypt Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 79. South Africa Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 80. South Africa Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 81. Israel Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 82. Israel Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 83. Turkey Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 84. Turkey Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 85. GCC Countries Respiratory Diseases Drugs Consumption Growth 2015-2020 (K Units)
Figure 86. GCC Countries Respiratory Diseases Drugs Value Growth 2015-2020 ($ Millions)
Figure 87. Global Respiratory Diseases Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 88. Global Respiratory Diseases Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 89. Americas Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 90. Americas Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 91. APAC Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 92. APAC Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 93. Europe Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 94. Europe Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 95. Middle East & Africa Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 96. Middle East & Africa Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 97. United States Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 98. United States Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 99. Canada Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 100. Canada Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 101. Mexico Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 102. Mexico Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 103. Brazil Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 104. Brazil Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 105. China Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 106. China Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 107. Japan Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 108. Japan Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 109. Korea Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 110. Korea Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 111. Southeast Asia Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 112. Southeast Asia Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 113. India Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 114. India Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 115. Australia Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 116. Australia Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 117. Germany Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 118. Germany Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 119. France Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 120. France Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 121. UK Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 122. UK Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 123. Italy Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 124. Italy Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 125. Russia Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 126. Russia Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 127. Spain Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 128. Spain Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 129. Egypt Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 130. Egypt Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 131. South Africa Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 132. South Africa Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 133. Israel Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 134. Israel Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 135. Turkey Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 136. Turkey Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 137. GCC Countries Respiratory Diseases Drugs Consumption 2021-2025 (K Units)
Figure 138. GCC Countries Respiratory Diseases Drugs Value 2021-2025 ($ Millions)
Figure 139. Biogen Respiratory Diseases Drugs Market Share (2018-2020)
Figure 140. Novartis Respiratory Diseases Drugs Market Share (2018-2020)
Figure 141. Pfizer Respiratory Diseases Drugs Market Share (2018-2020)
Figure 142. Novartis Respiratory Diseases Drugs Market Share (2018-2020)
Figure 143. Johnson & Johnson Respiratory Diseases Drugs Market Share (2018-2020)
Figure 144. Teva Respiratory Diseases Drugs Market Share (2018-2020)
Figure 145. Merck Respiratory Diseases Drugs Market Share (2018-2020)
Figure 146. EliLilly Respiratory Diseases Drugs Market Share (2018-2020)
Figure 147. AstraZeneca Respiratory Diseases Drugs Market Share (2018-2020)
Figure 148. Otsuka Respiratory Diseases Drugs Market Share (2018-2020)
Figure 149. Takeda Respiratory Diseases Drugs Market Share (2018-2020)


★調査レポート[世界の呼吸器疾患治療薬市場予測 2020年-2025年] (コード:LPI21MA10424)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の呼吸器疾患治療薬市場予測 2020年-2025年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆